Danaher has agreed to acquire Aldevron, a manufacturer of plasmid DNA, mRNA, and recombinant proteins for projects ranging from early-stage research to clinical trials and commercial applications. The deal, which is worth approximately US$9.6 B, aligns with Danaher’s expansion strategies for life sciences business through bolt-on acquisitions. Interestingly, the Aldevron deal comes a little more than a year after the acquisition of the biopharma business from General Electric Company’s life science division, now known as Cytiva. With Aldevron, Danaher will be able to leverage former’s capabilities in the field of genomic medicine.